Structure Therapeutics is trading at $48.14 (+4.58%) today, driven by recent positive Phase 2b trial results for its oral GLP-1 obesity drug aleniglipron, which showed durable weight loss beyond 36 weeks and improved tolerability.
-
The stock's resilience is further supported by high institutional interest, with Principal Financial Group significantly increasing its stake and other hedge funds modifying their holdings.
-
This gain occurs despite a broader market downturn, with the Nasdaq sinking 1.81% and chip stocks leading a general sell-off.